CHRS

Coherus Oncology is a commercial-stage immuno-oncology company with an FDA-approved PD-1 inhibitor antibody called LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma, along with two mid-stage clinical-stage monoclonal antibody candidates: casdozokitug (CHS-388), an IL-27 antagonist for hepatocellular carcinoma and other solid tumors, and tagmokitug (CHS-114), an afucosylated anti-CCR8 antibody for head and neck squamous cell carcinoma and other cancers. The company is developing these pipeline candidates in combination with LOQTORZI and partnered agents to overcome immune resistance across multiple solid tumor indications including liver, head and neck, colorectal, esophageal, upper gastrointest

Pipeline

Catalyst Calendar